Serotonin 

 448 Products   448 Products   1070 Diseases   113911 News 


«12...5960616263646566676869...11171118»
  • ||||||||||  olanzapine / Generic mfg.
    Journal, Adverse events:  Urinary Incontinence: A Rare Adverse Effect of Olanzapine. (Pubmed Central) -  Mar 25, 2024   
    Treatment of depression in smokers with sertraline might require higher doses and duration, with more frequent reviews. No abstract available
  • ||||||||||  risperidone / Generic mfg.
    Journal:  Induced erotomania by online romance fraud - a novel form of de Cl (Pubmed Central) -  Mar 25, 2024   
    No abstract available This case underscores the complex interplay between mental health, online activities, and the consequences of delusions, including suicidal thoughts, shedding light on the need for a comprehensive approach in addressing such challenging psychiatric scenarios.
  • ||||||||||  clozapine / Generic mfg.
    Journal:  Structural basis of ligand recognition and design of antihistamines targeting histamine H4 receptor. (Pubmed Central) -  Mar 25, 2024   
    Here, we report four cryo-EM structures of H4R/Gi complexes, with either histamine or synthetic agonists clobenpropit, VUF6884 and clozapine bound...The structural insight into H4R ligand binding allows us to identify mutants at E1825.46 for which the agonist clobenpropit acts as an inverse agonist and to correctly predict inverse agonism of a closely related analog with nanomolar potency. Together with the findings regarding receptor activation and Gi engagement, we establish a framework for understanding H4R signaling and provide a rational basis for designing novel antihistamines targeting H4R.
  • ||||||||||  Lybalvi (olanzapine/samidorphan) / Alkermes
    Retrospective data, Review, Journal:  Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Mar 25, 2024   
    Drug discontinuation incidence was higher in the OLZSAM group: RR = 1.22; 95% CI = 0.84-1.79; p = 0.30. The combination OLZSAM showed comparable efficacy to olanzapine alone in schizophrenia patients, with relatively less incidence of weight gain and adverse events; however, the drug discontinuation due to adverse events was more in the OLZSAM group.
  • ||||||||||  fluvoxamine / Generic mfg.
    Review, Journal:  Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis. (Pubmed Central) -  Mar 25, 2024   
    Additionally, depressive symptoms often precede the onset of MS. Given the role of the XBP1-sigma-1 receptor complex in the endoplasmic reticulum during EBV reactivation, the author proposes that fluvoxamine, an antidepressant with sigma-1 receptor agonism, could be a suitable therapeutic drug for MS.
  • ||||||||||  quetiapine / Generic mfg.
    Preclinical, Journal:  Quetiapine improves sensorimotor gating deficit in a sleep deprivation-induced rat model. (Pubmed Central) -  Mar 25, 2024   
    This manuscript seeks to aid the risk assessment process of NDXT in duloxetine drug products through providing a fast and reliable quantitative LC-MS/MS analytical method. Our results showed short- and long-term administration of QET improved sensorimotor gating deficit in 72
  • ||||||||||  agomelatine / Generic mfg.
    Journal:  Repurposed drug agomelatine is therapeutic against collagen-induced arthritis via iNOS targeting. (Pubmed Central) -  Mar 25, 2024   
    The selective conversion of readily available phenyl rings into high-value seven-membered rings offers a promising avenue for the construction of diversified and drug-like DNA-encoded library. AOM is therapeutic against CIA via inhibition of the iNOS/ERK/p65 signaling pathway after binding with iNOS.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  A Treatment Algorithm for High-Tone Pelvic Floor Dysfunction. (Pubmed Central) -  Mar 25, 2024   
    A stepwise approach to the treatment of HTPFD is recommended, with patients often necessitating multiple lines of treatment either sequentially or in conjunction. However, PFPT should be offered first line.
  • ||||||||||  mesdopetam (IRL790) / Ipsen, Nuplazid (pimavanserin) / Acadia Pharma
    Preclinical, Journal:  Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis. (Pubmed Central) -  Mar 25, 2024   
    Other drug-induced neurophysiological features were more specific to each treatment, affecting network oscillation frequencies and entropy, pointing to discrete differences in mechanisms of action. These findings indicate that neurophysiological characterization of brain states is particularly informative when evaluating therapeutic mechanisms in conditions involving symptoms that are difficult to assess in rodents such as psychosis, and that mesdopetam should be further explored as a potential novel antipsychotic treatment option for Parkinson psychosis.
  • ||||||||||  Preclinical, Journal:  Impaired neuronal macroautophagy in the prelimbic cortex contributes to comorbid anxiety-like behaviors in rats with chronic neuropathic pain. (Pubmed Central) -  Mar 24, 2024   
    Taken together, our work identifies causal linkage between PrL neuronal macroautophagy dysfunction and comorbid anxiety in neuropathic pain and provides novel insights into the role of PrL by differentiating its contribution in pain-induced comorbid anxiety from its modulation over general anxiety-like behaviors.Abbreviation: AAV: adeno-associated viruses; ACC: anterior cingulate cortex; ATG5: autophagy related 5; ATG7: autophagy related 7; ATG12: autophagy related 12; CAMK2/CaMKII: calcium/calmodulin-dependent protein kinase II; CNO: clozapine-N-oxide; CQ: chloroquine; DIA: data independent acquisition; DIO: double floxed inverse orf; DLG4/PSD-95: discs large MAGUK scaffold protein 4; Dox: doxycycline; GABA: ?-aminobutyric acid; GFP: green fluorescent protein; GO: gene ontology; Gi: inhibitory guanine nucleotide-binding proteins; HsCHRM4/M4D: human cholinergic receptor muscarinic 4; HsSYN: human synapsin; KEGG: Kyoto encyclopedia of genes and genomes; LAMP1: lysosomal-associated membrane protein 1; LC3-II: PE conjugated microtubule-associated protein 1 light chain3; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; mPFC: medial prefrontal cortex; P2A: 2A self-cleaving peptide; PPI: protein-protein interaction networks; PrL: prelimbic cortex; RBFOX3/NeuN: RNA binding protein, fox-1 homolog (C. elegans) 3; rtTA: reverse tetracycline-transactivator; SDS-PAGE: sodium dodecylsulfate-polyacrylamide gel electrophoresis; SHANK3: SH3 and multiple ankyrin repeat domains 3; SLC1A1/EAAC1: solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, systemXag), member 1; SNAP23: synaptosomal-associated protein 23; SNI:spared nerve injury; SQSTM1/p62: sequestosome 1; SYT3: synaptotagmin 3; TRE: tetracycline-responsive element; TRE3G: third-generation tetracycline-responsive element.
  • ||||||||||  Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
    Preclinical, Journal:  Modulating gut microbiota improves neurological function and depressive symptoms in rats with post-stroke depression (Pubmed Central) -  Mar 23, 2024   
    This finding supports individual off-label treatment attempts. In PSD rats, TMAO/H2S ratio is correlated with neurological function score, immobility time in forced swimming and sugar water preference, and modulating intestinal flora can improve neurological function and depressive symptoms and improve the integrity of the blood-brain barrier.
  • ||||||||||  Trintellix (vortioxetine) / Lundbeck, Takeda
    Clinical, Journal:  Assessing the (Pubmed Central) -  Mar 23, 2024   
    P2
    In PSD rats, TMAO/H2S ratio is correlated with neurological function score, immobility time in forced swimming and sugar water preference, and modulating intestinal flora can improve neurological function and depressive symptoms and improve the integrity of the blood-brain barrier. Overall, vortioxetine significantly improved depressive symptoms
  • ||||||||||  Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
    Hypercalcemia related to Paliperidone in ESRD patient () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_682;    
    58 year-old male with diabetes,schizo affective disorder,ESRD on hemodialysis had hypercalcemia on monthly dialysis labs.Being on dialysis for a year,his mineral bone disease was well controlled without requiring any phosphate binders or calcimimetics.Home meds were insulin,ability and benztropine.Due to uncontrolled schizoaffective disorder,monthly paliperidone injection was started which helped his symptoms remarkably.Within few months of starting paliperidone,we noted a strange association of hypercalcemia,which couldn't be explained otherwise.Calcium stayed above 10.5 mg/dl the week or following week of getting injection paliperidone while it normalized 3-4 weeks later.PTH levels were between 300-450 while his phosphorus stayed in range 3.5-4.5.Hypercalcemia workup for malignancy,paraproteinemia,Vit D intoxication,granulomatous disorders were negative.He wasn't on calcium-based binders or calcium supplement nor taking common hypercalcemia causing drugs like thiazide or lithium.He was not limited by mobility.His prolactin was elevated at 192. Hypercalcemia workup should include atypical antipsychotics drugs in schizoaffective ESRD patients.
  • ||||||||||  Nulojix (belatacept) / BMS
    Catatonia post kidney transplant () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_630;    
    Tacrolimus dose was adjusted to a level of 4 to 6; venlafaxine and trazodone were started...Lorazepan was increased but the decision was made to wean patient off of tacrolimus and start belatacept...Seen in both liver and kidney transplant recipients from less than one month to several years post transplant and attributed to CNI induced neurotoxicity, more with tacrolimus than cyclosporine. Close monitoring of CNI treated patients with any psychiatric history is warranted.
  • ||||||||||  Bridion (sugammadex) / Merck (MSD)
    Idiopathic Fanconi Syndrome after a Vascular Surgery () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_589;    
    The abrupt postoperative onset of these finding, suggest an acquired cause of FS, possibly due to a medication. A proposed cause was Vancomycin, since it was a new medication and it has been linked in the literature to nephrotoxicity, including proximal tubule dysfunction.
  • ||||||||||  Myrbetriq (mirabegron) / Astellas, Tetralysal (lymecycline) / Galderma
    Computational drug repurposing screen targeting PLA2R antibody binding. (Focussed Oral Room 2) -  Mar 23, 2024 - Abstract #ERAEDTA2024ERA_EDTA_1677;    
    The compounds identified for investigation are used for an array of different health conditions. However, they all share the chemical properties of large molecular weight and have the potential to form multiple hydrogen bonds.
  • ||||||||||  Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
    Journal:  Dual disorder: does expert clinical experience support the rationale for cariprazine use? (Pubmed Central) -  Mar 22, 2024   
    In conclusion, the panel recommends that individuals with DD should be cared for in a single center. Pharmacologic treatment in individuals with DD needing both control of symptoms related to schizophrenia spectrum disorders and substance withdrawal should ideally be based on using a non-sedative antipsychotic with anti-craving activity.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  Factors Associated With Onabotulinum Toxin-A Discontinuation in a Diverse Urban Population. (Pubmed Central) -  Mar 22, 2024   
    Patients who reported nocturia and UUI before injection were more likely to continue BTX-A suggesting more severe OAB is more responsive to this therapy. Given the large proportion (>40%) of patients who discontinued BTX-A treatment, further research is needed to identify barriers to continuation of care.
  • ||||||||||  sertraline / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Surgery, Bariatric surgery:  ANTILOP: Pharmacokinetics and Pharmacodynamics of Oral Sertraline Before and After Bariatric Surgery (clinicaltrials.gov) -  Mar 22, 2024   
    P=N/A,  N=3, Terminated, 
    Ped Thai Su Phai (Thai Ducks Fighting Danger) social giver group. N=30 --> 3 | Trial completion date: Dec 2027 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Nov 2023; Problem with recruiting as a consequence of COVID-19